Dipeptidyl peptidase 4 inhibitor reduces tumor-associated macrophages and enhances anti-PD-L1-mediated tumor suppression in non-small cell lung cancer

PURPOSE: The efficacy of immune checkpoint inhibitors such as programmed cell death ligand 1 (PD-L1) antibodies in non-small cell lung cancer (NSCLC) is limited, and combined use with other therapies is recommended. Dipeptidyl peptidase 4 (DPP4) inhibitors, a class of small molecule inhibitors, are...

Descripción completa

Detalles Bibliográficos
Autores principales: Zuo, Bei, Li, Tao, Liu, Xiaoyun, Wang, Shuling, Cheng, Jianxiang, Liu, Xiangqun, Cui, Wenjie, Shi, Hengliang, Ling, Chunhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10514125/
https://www.ncbi.nlm.nih.gov/pubmed/37115489
http://dx.doi.org/10.1007/s12094-023-03187-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10514125/
https://www.ncbi.nlm.nih.gov/pubmed/37115489
http://dx.doi.org/10.1007/s12094-023-03187-5

Ejemplares similares